Patients’ characteristics (discovery cohort)
| Variable . | Discovery cohort (N = 48 patients) . |
|---|---|
| COO (NanoString), n (%) | |
| ABC | 7 (15) |
| GCB | 33 (69) |
| UNC | 8 (16) |
| MYC/BCL-2 DEXP mRNA, n (%) | |
| Yes | 10 (21) |
| No | 38 (79) |
| IPI, n (%) | |
| Low (0-2) | 25 (52) |
| High (3-5) | 23 (48) |
| Sex, n (%) | |
| Female | 24 (50) |
| Male | 24 (50) |
| Age, y, median (range) | 63 (17-89) |
| Stage, n (%) | |
| I | 3 (6) |
| II | 10 (21) |
| III | 5 (10) |
| IV | 30 (62) |
| Follow-up, mo, median (range) | 53.97 (2.66-110.85) |
| Variable . | Discovery cohort (N = 48 patients) . |
|---|---|
| COO (NanoString), n (%) | |
| ABC | 7 (15) |
| GCB | 33 (69) |
| UNC | 8 (16) |
| MYC/BCL-2 DEXP mRNA, n (%) | |
| Yes | 10 (21) |
| No | 38 (79) |
| IPI, n (%) | |
| Low (0-2) | 25 (52) |
| High (3-5) | 23 (48) |
| Sex, n (%) | |
| Female | 24 (50) |
| Male | 24 (50) |
| Age, y, median (range) | 63 (17-89) |
| Stage, n (%) | |
| I | 3 (6) |
| II | 10 (21) |
| III | 5 (10) |
| IV | 30 (62) |
| Follow-up, mo, median (range) | 53.97 (2.66-110.85) |
ABC, activated B-cell; DEXP, double expressor; GCB, germinal center B-cell; IPI, international prognostic index; UNC, unclassified.